STADA Acquires Triple Combo Pump Therapy, Seeks European Approvals
STADA Arzneimittel has announced the acquisition of Sweden-based Lobsor Pharmaceuticals, gaining the rights to its triple-combination therapy of levodopa, carbidopa, and entacapone, delivered via modern pump technology, as a treatment for patients with late-stage Parkinson’s disease. The triple-combo treatment has already been approved in most…